IN2015DN00914A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN00914A IN2015DN00914A IN914DEN2015A IN2015DN00914A IN 2015DN00914 A IN2015DN00914 A IN 2015DN00914A IN 914DEN2015 A IN914DEN2015 A IN 914DEN2015A IN 2015DN00914 A IN2015DN00914 A IN 2015DN00914A
- Authority
- IN
- India
- Prior art keywords
- methods
- etk
- txk
- bmx
- itk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions con taining them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not lim ited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680231P | 2012-08-06 | 2012-08-06 | |
US13/843,554 US9034885B2 (en) | 2012-01-13 | 2013-03-15 | EGFR modulators and uses thereof |
US201361814147P | 2013-04-19 | 2013-04-19 | |
US13/917,514 US8685988B2 (en) | 2012-08-06 | 2013-06-13 | EGFR modulators and uses thereof |
PCT/US2013/050163 WO2014025486A1 (en) | 2012-08-06 | 2013-07-11 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN00914A true IN2015DN00914A (en) | 2015-06-12 |
Family
ID=50068479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN914DEN2015 IN2015DN00914A (en) | 2012-08-06 | 2013-07-11 |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP3170825B1 (en) |
JP (2) | JP6215938B2 (en) |
KR (1) | KR102181365B1 (en) |
CN (2) | CN103748096B (en) |
AU (1) | AU2013300106B2 (en) |
BR (1) | BR112015002709B1 (en) |
CA (1) | CA2881275C (en) |
CY (1) | CY1120844T1 (en) |
DK (1) | DK2880035T3 (en) |
ES (2) | ES2733576T3 (en) |
HK (1) | HK1210471A1 (en) |
HR (1) | HRP20170311T1 (en) |
HU (1) | HUE031955T2 (en) |
IN (1) | IN2015DN00914A (en) |
LT (1) | LT2880035T (en) |
MX (1) | MX361992B (en) |
NZ (1) | NZ629807A (en) |
PT (1) | PT2880035T (en) |
RU (2) | RU2018104702A (en) |
SG (1) | SG11201500872SA (en) |
WO (1) | WO2014025486A1 (en) |
ZA (2) | ZA201500762B (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2671748T3 (en) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
JP6353788B2 (en) * | 2012-01-13 | 2018-07-04 | エイシア バイオサイエンシーズ インコーポレイテッド | Heterocyclic compounds as anticancer agents and their use |
CA2897985A1 (en) * | 2013-01-16 | 2014-07-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
DK2970205T3 (en) | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2 and ALK2 inhibitors and methods for their use |
CN112592334B (en) * | 2013-07-11 | 2023-10-27 | 艾森医药公司 | Pyrimidine derivatives as kinase inhibitors |
WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
CA2955009A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
CN107801397B (en) * | 2015-02-13 | 2021-07-30 | 达纳-法伯癌症研究所公司 | LRRK2 inhibitors and methods of making and using the same |
JP2018104290A (en) * | 2015-04-28 | 2018-07-05 | アステラス製薬株式会社 | Pharmaceutical composition containing pyrazinecarboxamide compound as active ingredient |
CN107614503B (en) | 2015-04-29 | 2020-03-10 | 广东众生药业股份有限公司 | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors |
WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
CA3001744A1 (en) * | 2015-10-09 | 2017-04-13 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
CN105646496B (en) * | 2016-01-20 | 2018-07-20 | 华侨大学 | A kind of 7H- pyrrolo-es [2,3-d] pyrimidine derivatives, its synthetic method and application |
CN107540661A (en) * | 2016-06-24 | 2018-01-05 | 正大天晴药业集团股份有限公司 | Crystallization as the Aniline pyrimidine compound of EGFR inhibitor |
CN107663207B (en) * | 2016-07-27 | 2021-07-30 | 南京圣和药业股份有限公司 | Mesylate crystal of EGFR kinase inhibitor and preparation method thereof |
CN107663208B (en) * | 2016-07-27 | 2021-10-15 | 南京圣和药业股份有限公司 | Medicinal salt of novel EGFR kinase inhibitor and preparation method and application thereof |
CN107955019B (en) * | 2016-10-17 | 2021-09-14 | 广东众生药业股份有限公司 | Salt form and crystal form of EGFR inhibitor and preparation method thereof |
CN106749266B (en) * | 2016-11-14 | 2019-01-22 | 山东大学 | The high efficiency preparation method of pyrrolo- [2,3-d] pyrimidines |
CN108299419B (en) * | 2017-01-11 | 2022-04-26 | 南京圣和药业股份有限公司 | Novel crystal forms of novel EGFR kinase inhibitor and preparation method thereof |
WO2018145525A1 (en) * | 2017-02-08 | 2018-08-16 | 中国医药研究开发中心有限公司 | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof |
CA3059072A1 (en) * | 2017-04-07 | 2018-10-11 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
CN109422751B (en) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | Compound with activity of degrading tyrosine protein kinase JAK3 |
US11709156B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved analytical analysis |
US11709155B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
JP6995428B2 (en) * | 2017-12-28 | 2022-01-14 | デウン ファーマシューティカル カンパニー リミテッド | Oxy-fluoropiperidine derivative as a kinase inhibitor |
KR102577241B1 (en) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | Amino-fluoropiperidine derivatives as kinase inhibitor |
KR102577242B1 (en) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | Amino-methylpiperidine derivatives as kinase inhibitor |
KR20210003780A (en) | 2018-04-05 | 2021-01-12 | 스미토모 다이니폰 파마 온콜로지, 인크. | AXL kinase inhibitors and uses thereof |
CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
CN108530450B (en) * | 2018-05-03 | 2021-03-30 | 赖建智 | Compound with EGFR (epidermal growth factor receptor) inhibitory activity, preparation method and application of compound in disease treatment |
MX2021000977A (en) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same. |
EP3613738A1 (en) * | 2018-08-23 | 2020-02-26 | Lead Discovery Center GmbH | 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer |
KR20210146290A (en) | 2019-02-12 | 2021-12-03 | 스미토모 다이니폰 파마 온콜로지, 인크. | Formulations comprising heterocyclic protein kinase inhibitors |
CN111747950B (en) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | Pyrimidine derivatives for the treatment of cancer |
CN110407840A (en) * | 2019-08-15 | 2019-11-05 | 重庆化工职业学院 | A kind of Ai Wei replaces the preparation method of Buddhist nun |
CN117551103A (en) * | 2019-11-13 | 2024-02-13 | 浙江龙传生物医药科技有限公司 | Pyrrolo-pyrimidine compound as BTK inhibitor and application thereof |
US11918936B2 (en) | 2020-01-17 | 2024-03-05 | Waters Technologies Corporation | Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding |
CN115023428A (en) * | 2020-01-21 | 2022-09-06 | 江苏先声药业有限公司 | Pyrimidopyrroles |
CN111848631B (en) * | 2020-08-28 | 2022-04-19 | 四川大学华西医院 | Pyrrolo [2,3-d ] pyrimidine derivative targeting EGFR mutation and preparation method and application thereof |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
CN114957248B (en) * | 2022-05-09 | 2023-12-29 | 南开大学 | Pyrrolo pyrimidine compound and preparation method, pharmaceutical composition and application thereof |
CN115611989B (en) * | 2022-10-09 | 2023-08-01 | 武汉理工大学 | Optimized preparation method and application of mechanical activated starch derivative inhibitor |
WO2024092047A1 (en) | 2022-10-26 | 2024-05-02 | Sorrento Therapeutics, Inc. | Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis |
WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5563905A (en) | 1992-09-24 | 1996-10-08 | Hughes Aircraft Company | Network communication system having time-sliced protocol |
EP1539992B1 (en) | 2002-07-20 | 2009-11-11 | Acea Biosciences, Inc. | Impedance based devices and methods for use in assays |
US7560269B2 (en) | 2002-12-20 | 2009-07-14 | Acea Biosciences, Inc. | Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays |
US7468255B2 (en) | 2002-12-20 | 2008-12-23 | Acea Biosciences | Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology |
US7470533B2 (en) | 2002-12-20 | 2008-12-30 | Acea Biosciences | Impedance based devices and methods for use in assays |
US7732127B2 (en) | 2002-12-20 | 2010-06-08 | Acea Biosciences, Inc. | Dynamic monitoring of cell adhesion and spreading using the RT-CES system |
CA2550274A1 (en) | 2003-11-12 | 2005-05-26 | Acea Biosciences, Inc. | Real time electronic cell sensing systems and applications for cell-based assays |
WO2007039404A1 (en) * | 2005-09-21 | 2007-04-12 | Nycomed Gmbh | Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles |
EP2440559B1 (en) * | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
US20110207736A1 (en) * | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
-
2013
- 2013-07-11 CN CN201380001359.4A patent/CN103748096B/en active Active
- 2013-07-11 BR BR112015002709-1A patent/BR112015002709B1/en active IP Right Grant
- 2013-07-11 SG SG11201500872SA patent/SG11201500872SA/en unknown
- 2013-07-11 LT LTEP13745491.4T patent/LT2880035T/en unknown
- 2013-07-11 ES ES16202341T patent/ES2733576T3/en active Active
- 2013-07-11 CA CA2881275A patent/CA2881275C/en active Active
- 2013-07-11 ES ES13745491.4T patent/ES2618007T3/en active Active
- 2013-07-11 RU RU2018104702A patent/RU2018104702A/en not_active Application Discontinuation
- 2013-07-11 EP EP16202341.0A patent/EP3170825B1/en active Active
- 2013-07-11 HU HUE13745491A patent/HUE031955T2/en unknown
- 2013-07-11 KR KR1020157006007A patent/KR102181365B1/en active IP Right Grant
- 2013-07-11 DK DK13745491.4T patent/DK2880035T3/en active
- 2013-07-11 NZ NZ629807A patent/NZ629807A/en not_active IP Right Cessation
- 2013-07-11 CN CN201710229308.7A patent/CN107266453B/en active Active
- 2013-07-11 IN IN914DEN2015 patent/IN2015DN00914A/en unknown
- 2013-07-11 EP EP13745491.4A patent/EP2880035B9/en active Active
- 2013-07-11 RU RU2015107831A patent/RU2645672C2/en active
- 2013-07-11 AU AU2013300106A patent/AU2013300106B2/en active Active
- 2013-07-11 PT PT137454914T patent/PT2880035T/en unknown
- 2013-07-11 MX MX2015001715A patent/MX361992B/en active IP Right Grant
- 2013-07-11 JP JP2015526540A patent/JP6215938B2/en active Active
- 2013-07-11 WO PCT/US2013/050163 patent/WO2014025486A1/en active Application Filing
-
2015
- 2015-02-02 ZA ZA2015/00762A patent/ZA201500762B/en unknown
- 2015-11-16 HK HK15111282.7A patent/HK1210471A1/en unknown
-
2016
- 2016-01-29 ZA ZA2016/00648A patent/ZA201600648B/en unknown
-
2017
- 2017-01-17 JP JP2017005935A patent/JP2017061581A/en not_active Withdrawn
- 2017-02-23 HR HRP20170311TT patent/HRP20170311T1/en unknown
- 2017-03-02 CY CY171100274T patent/CY1120844T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN00914A (en) | ||
MX2018004332A (en) | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same. | |
NZ715687A (en) | Pyrimidine derivatives as kinase inhibitors | |
MX2013013294A (en) | Tyrosine kinase inhibitors. | |
PH12016500531A1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
MY159327A (en) | Jak kinase modulating quinazoline derivatives and methods of use thereof | |
EA201492176A1 (en) | SELECTIVE PI3K DELTA INHIBITORS | |
CL2009001212A1 (en) | Compounds derived from pyrrolo [2,3-d] pyrimidine, kinase inhibitors; pharmaceutical composition comprising them; and its use in the treatment of vascular dementia, CNS disorder, cancer, among others. | |
GT201400301A (en) | 7H-PIRROLO [2,3-D] PYRIMIDINS-4- (AMINHO-SUBSTITUTES) NOVELTY AS INHIBITORS OF LRRK2 | |
EA201891067A1 (en) | [1,2,4] TRIAZOLO [1,5-a] PYRIMIDIN-7-ILY COMPOUND | |
MX361815B (en) | Pyrazolopyrimidine compounds as kinase inhibitors. | |
BR112015010663A8 (en) | sustained release oral dosage forms, and use of ruxolitinib or a pharmaceutically acceptable salt thereof | |
PH12015501955B1 (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
GEP20156333B (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
EA201691930A1 (en) | SUBSTITUTED DERIVATIVES 4,5,6,7-TETRAHYDROPYRAZOLO [1,5-α] PYRAZINE AND DERIVATIVES 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO [1,5-α] [1,4] DIAZEPIN AS AN INHIBITORS ROS1 | |
EA201991109A1 (en) | [1,2,4] TRIAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | |
WO2012030944A3 (en) | Quinoline and isoquinoline derivatives for use as jak modulators | |
NZ703343A (en) | Phenyl amino pyrimidine bicyclic compounds and uses thereof | |
EA201991094A1 (en) | COMPOUNDS [1,2,4] TRIAZOLO [1,5-a] PYRIMIDINE AS PDE2 INHIBITORS | |
EA201990973A1 (en) | COMPOUNDS [1,2,4] TRIAZOLO [1,5-a] PYRIMIDINE AS PDE2 INHIBITORS | |
BR112015000459A2 (en) | phosphodiesterase enzyme inhibitors 10 | |
PH12018500796A1 (en) | Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide | |
CY1122837T1 (en) | TREATMENT OF Alopecia areata | |
CY1115157T1 (en) | KINAZOLINE DERIVATIVES OF JAK KINASE REGULATORS AND METHODS OF USE |